LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2. - Dataset (ID:20238)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 13 of 483
Next
>>
>
301 to 325 of 12072 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Relative Growth Rate After Treatment
BT-20	TGX221	0.04	uM	LJP5	1	H24	72	hr	1334	3277	3970	0.8253	0.7368
BT-20	TGX221	0.04	uM	LJP5	2	H24	72	hr	1334	3787	3970	0.9537	0.9302
BT-20	TGX221	0.04	uM	LJP5	3	H24	72	hr	1334	3720	3970	0.9368	0.9048
BT-20	Torin1	0.04	uM	LJP6	1	O18	72	hr	1334	2207	3970	0.5558	0.3309
BT-20	Torin1	0.04	uM	LJP6	2	O18	72	hr	1334	2161	3970	0.5442	0.3135
BT-20	Torin1	0.04	uM	LJP6	3	O18	72	hr	1334	2041	3970	0.5140	0.2679
BT-20	Torin2	0.04	uM	LJP5	1	I24	72	hr	1334	1284	3970	0.3234	-0.0192
BT-20	Torin2	0.04	uM	LJP5	2	I24	72	hr	1334	1321	3970	0.3327	-0.0052
BT-20	Torin2	0.04	uM	LJP5	3	I24	72	hr	1334	1246	3970	0.3138	-0.0336
BT-20	Tozasertib	0.04	uM	LJP5	1	B18	72	hr	1334	1673	3970	0.4213	0.1283
BT-20	Tozasertib	0.04	uM	LJP5	2	B18	72	hr	1334	1885	3970	0.4747	0.2088
BT-20	Tozasertib	0.04	uM	LJP5	3	B18	72	hr	1334	2277	3970	0.5734	0.3575
BT-20	Trametinib	0.04	uM	LJP5	1	P24	72	hr	1334	3109	3970	0.7829	0.6731
BT-20	Trametinib	0.04	uM	LJP5	2	P24	72	hr	1334	2925	3970	0.7366	0.6033
BT-20	Trametinib	0.04	uM	LJP5	3	P24	72	hr	1334	3431	3970	0.8640	0.7952
BT-20	TWS119	0.04	uM	LJP5	1	M06	72	hr	1334	4166	3970	1.0491	1.0740
BT-20	TWS119	0.04	uM	LJP5	2	M06	72	hr	1334	4238	3970	1.0673	1.1013
BT-20	TWS119	0.04	uM	LJP5	3	M06	72	hr	1334	4233	3970	1.0660	1.0994
BT-20	Vemurafenib	0.04	uM	LJP5	1	C18	72	hr	1334	3410	3970	0.8588	0.7872
BT-20	Vemurafenib	0.04	uM	LJP5	2	C18	72	hr	1334	3913	3970	0.9854	0.9780
BT-20	Vemurafenib	0.04	uM	LJP5	3	C18	72	hr	1334	4169	3970	1.0499	1.0751
BT-20	Withaferin A	0.04	uM	LJP5	1	G18	72	hr	1334	3828	3970	0.9640	0.9458
BT-20	Withaferin A	0.04	uM	LJP5	2	G18	72	hr	1334	4113	3970	1.0358	1.0539
BT-20	Withaferin A	0.04	uM	LJP5	3	G18	72	hr	1334	4201	3970	1.0579	1.0873
BT-20	Withaferin A	0.04	uM	LJP6	1	G18	72	hr	1334	3772	3970	0.9499	0.9246

|<
<<
Previous
Page 13 of 483
Next
>>
>
301 to 325 of 12072 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2. - Dataset (ID:20238)